Rationale: Primary carcinosarcoma of the upper urinary tract is rare. Ureteral duplication is one of the most common urinary tract malformations. Additionally, the association between ureteral duplication and malignancy is unknown. To the best of our knowledge, no cases of malignant tumors diagnosed as carcinosarcoma with ureteral duplication have been reported. We herein report the case of a patient with carcinosarcoma of the ureteropelvic junction associated with incomplete ureteral duplication.
Introduction
Carcinosarcoma is a biphasic neoplasm with mixed malignant epithelial and mesenchymal components whose definition and histogenesis have long been discussed. [1] [2] [3] [4] [5] [6] [7] [8] [9] This neoplasm is highly aggressive in general and is often associated with poor prognosis. Carcinosarcoma is rare but can occur in a variety of organs or systems, such as the uterus, ovary, lung, breast, esophagus, and urinary tract. For the urinary tract, the majority of reported cases of carcinosarcomas are cases of the lower urinary tract, predominantly located in the urinary bladder. Several clinicopathological studies with a series of carcinosarcoma cases of the urinary bladder have been published. [8] [9] [10] [11] In contrast, there have been only approximately 20 cases of carcinosarcoma of the upper urinary tract reported to date. Due to its rarity, the clinicopathological features of carcinosarcoma of the upper urinary tract remain incompletely elucidated.
Ureteral duplication is one of the most common urinary tract malformations found in approximately 0.8% of autopsy series. [12] There are 2 subtypes of duplicated ureter; complete ureteral duplication refers to 2 separate ureters with 2 separate orifices in the bladder, while incomplete ureteral duplication refers to 2 ureters joining together to form a single ureter before entering the bladder. Embryologically, complete ureteral duplication occurs when 2 separate ureteric buds arise from the mesonephric duct, while incomplete ureteral duplication is caused by premature bifurcation of a single ureteric bud prior to fusion with metanephros. [13] Complications of ureteral duplication include urinary reflux, ureterocele, and ureteral obstruction. [12, 14] However, the association between ureteral duplication and malignancy remains unclear.
Herein, we report a rare case of carcinosarcoma arising from the ureteropelvic junction (UPJ) of incomplete ureteral duplication. Informed consent for publication of this case report has been obtained from the patient. We also discuss the significance of distinguishing carcinosarcoma from another related entity and review the relevant literature.
Clinical summary
A 60-year-old Japanese woman presented with a several-day history of gross hematuria. She had no fever or pain. She had a history of total hysterectomy and postoperative adjuvant chemotherapy (paclitaxel and carboplatin) for endometrioid carcinoma (G1, pT1bN0) 5 years before. A preoperative CT scan revealed right unilateral incomplete ureteral duplication. Two months after the surgery, right hydronephrosis, which was not preoperatively present, was detected on CT scan, probably because of the ureteral stricture caused by postoperative scarring. A double-J ureteral stent was inserted and remained in place for 11 months. She developed pyelonephritis several times during the placement of the stent. One year and 7 months after the surgery, wall thickening at the UPJ of the lower moiety of the right kidney was observed on CT scan. Two years and 7 months after the surgery, a 6 mm polypoid nodule was detected at the right lower UPJ, whose size increased to 9 mm a year later. There were no signs of recurrence of endometrioid carcinoma. She also had histories of Wolff-Parkinson-White syndrome, splenectomy for thrombocytopenic purpura, glaucoma, hypercholesterolemia, and carpal tunnel syndrome and was a hepatitis B virus carrier. She had a 7-year history of smoking 10 cigarettes per day. She denied any occupational chemical exposure. She had no family history of urinary tract malignancy.
Retrograde pyelography showed right incomplete ureteral duplication, hydronephrosis, and a filling defect at the right lower UPJ (Fig. 1A) . A contrast-enhanced CT scan revealed a round, uniformly enhanced polypoid tumor 12 mm in diameter ( Fig. 1B) , which was 3 mm larger than that observed a year before. Cystoscopy showed no tumor in the bladder. Ureteroscopy revealed a nodular tumor at the right lower UPJ. Urine cytology showed a small amount of degenerated atypical epithelial and nonepithelial cells, which were indefinite for malignancy ( Fig. 2 ). Following cytology, the transureteral biopsy specimen showed dysplastic urothelial cells and atypical spindle cells. The atypical spindle cells were immunohistochemically positive for desmin and h-caldesmon, suggesting that there was a neoplasm with smooth muscle differentiation. With high suspicion of clinical malignancy, right nephroureterectomy was performed. The postoperative course was uneventful. The patient was followed up without additional therapy and remained alive without evidence of local recurrence or metastasis 21 months after the surgery.
Pathological findings
The tumor fell off of the UPJ during the surgical procedure and was submitted separately from the nephroureterectomy specimen for pathology ( Fig. 3) . Macroscopically, the tumor was 14 Â 10 mm in size and had a spherical shape with a smooth surface. It had no stalk, which made it difficult to identify the attachment site to the ureteral wall. The cut surface showed a solid, yellowish-white appearance with hemorrhage. Microscopically, the tumor consisted of two components: carcinomatous and sarcomatous components ( Fig. 4 ). The tumor predominantly consisted of the sarcomatous component, which exhibited proliferation of atypical spindle cells with fibrous cytoplasm and enlarged, hyperchromatic, irregularly shaped nuclei (Fig. 4I ). The surface of the tumor was covered with atypical epithelial cells with enlarged, hyperchromatic, irregularly shaped nuclei, which formed irregular glandular structures, suggestive of adenocarcinoma ( Fig. 4B and C) . A few nests of carcinomatous components were also observed inside the tumor ( Fig. 4D and E). Some of the carcinomatous components had intercellular bridges, suggesting squamoid differentiation. There was no obvious "transition" between the 2 components.
The immunohistochemical findings of the tumor are summarized in Table 1 . The carcinomatous component was positive for pancytokeratin (AE1/AE3; Leica Biosystems; Tokyo, Japan), low molecular weight cytokeratin (CAM 5.2; Becton Dickinson; San Jose, CA, USA), EMA (E29; Roche Diagnostics; Tokyo, Japan), E-cadherin (NCH-38; Nichirei Biosciences; Tokyo, Japan), GATA3 (L50-823; Biocare Medical; Pacheco, CA, USA), uroplakin 2 (BC21; Biocare Medical) (focal) and p63 (4A4; Nichirei Biosciences; Tokyo, Japan) (focal) and negative for vimentin (V9; Roche Diagnostics; Tokyo, Japan), desmin (D2-R-11; Leica Biosystems; Tokyo, Japan), h-caldesmon (h-CD; Agilent, Santa Clara, CA, USA), and a-SMA (1A4; Dako; Santa Clara, CA, USA) ( Fig. 4F-H) . In contrast, the sarcomatous component was positive for vimentin, desmin, h-caldesmon, and a-SMA and negative for all epithelial markers listed above . Anaplastic lymphoma kinase 1 (ALK-1; Dako; Santa Clara, CA, USA) was negative through the tumor. Based on these findings, we diagnosed the tumor as carcinosarcoma.
The nephroureterectomy specimen showed incomplete ureteral duplication, hydronephrosis, and ureteral dilation (Fig. 3A) . The tumor was likely to have originally located on the UPJ of the more severely dilated ureter. Microscopically, the ureteral mucosa of the more dilated mucosa showed severe inflammation with lymphoid follicle formation, while the other did not. However, we could not find any evidence of sarcoma, invasive carcinoma, carcinoma in situ or dysplastic epithelium in the background ureteral tissue. 
Discussion
Carcinosarcoma is a biphasic malignant tumor with carcinomatous and sarcomatous components. Sarcomatoid carcinoma is another term that is occasionally improperly used to refer to tumors exhibiting such features. Distinction between carcinosarcoma and sarcomatoid carcinoma has been a matter of controversy. The widely accepted criterion for distinguishing carcinosarcoma and sarcomatoid carcinoma is the presence or absence of epithelial characteristics in its sarcomatous component; carcinosarcoma lacks any immunohistochemical or ultrastructural evidence of epithelial differentiation in its sarcomatous component, whereas sarcomatoid carcinoma retains epithelial markers. [6, 7, 15, 16] Based on this definition, the present case corresponds to carcinosarcoma. However, according to the latest World Health Organization classification of tumors of the urinary system, all urothelial carcinomas with sarcomatous components are collectively classified as sarcomatoid variants of urothelial carcinomas. [17] The histogenesis of carcinosarcoma is hypothesized as follows: (1) collision tumor, which is developed through independent occurrences of carcinoma and sarcoma in close proximity that merge into one lesion; (2) composition tumor, which is developed through malignant transformation of both epithelial and mesenchymal components of the same tissue; (3) combination tumor, which is developed through divergent differentiation and malignant transformation of a single pluripotent stem cell; and (4) conversion tumor, which is developed through epithelial-tomesenchymal transition of carcinoma. [18, 19] In terms of clonality, the former 2 mechanisms are referred to as multiclonal theory, while the latter can be called monoclonal theory. The molecular evidence accumulated to date supports the monoclonal theory. [16, [20] [21] [22] Additionally, many studies have revealed that carcinomatous and sarcomatous components showed significant overlap of genetic aberrations, suggesting the late occurrence of divergent differentiation during tumor development. [16, 20, 21] In other words, the sarcomatous component of carcinosarcoma is likely derived from the carcinomatous component in most cases. For the present case, however, the histogenesis is uncertain because we did not perform genetic analysis.
Malignant neoplasms accompanied by ureteral duplication are extremely rare; only 23 cases have been registered in Englishlanguage publications to date ( Table 2 ). Among them, urothelial carcinoma predominated, and only 2 cases were reported as sarcomatoid carcinoma with uncertainty of epithelial marker expression in the sarcomatous component. [35, 40] Whether ureteral duplication is a risk factor for malignancy remains unclear. In contrast, horseshoe kidney, which is another common urinary tract malformation, is a risk factor for pelvic tumor. [12, 44] The higher incidence of pelvic tumors in horseshoe kidneys is attributed to chronic irritability, such as urinary stasis, urinary tract infection, and stone formation. [12, 44] Based on this speculation, it is reasonable to hypothesize that ureteral duplication is also a risk factor for malignancy because this anomaly is occasionally accompanied by urinary reflux and infection. Of note, 1 of the duplicated ureters of the present case, where the tumor is considered to have arisen, showed severe lymphocytic inflammation, which was evidently different from the other duplicate ureter.
The differential diagnosis of carcinosarcoma includes sarcomatoid carcinoma, carcinoma with reactive stromal proliferation, and carcinoma with a benign heterologous component. Sarcomatoid carcinoma can be differentiated by immunohistochemical studies based on the definition of carcinosarcoma/ sarcomatoid carcinoma mentioned above. Carcinomas with reactive stromal proliferation and benign heterologous components can be differentiated by careful examination for malignant cytohistological features. If the sarcomatous component shows smooth muscle differentiation, as in the present case, inflammatory myofibroblastic tumor should be distinguished. A recent study showed that ALK-1 protein expression and ALK gene rearrangement were identified in approximately 60% of inflammatory myofibroblastic tumor cases in the urinary bladder, while sarcomatoid urothelial carcinoma was negative for ALK-1 expression and ALK rearrangement, indicating the utility of these markers in differential diagnosis. [45] The prognosis of carcinosarcoma/sarcomatoid carcinoma of the upper urinary tract has not been systematically studied due to the paucity of cases. In the urinary bladder, to the best of our knowledge, 2 studies comparing the prognosis of carcinosarcoma and sarcomatoid carcinoma have been reported. [10, 11] One study of 41 cases showed no significant difference in survival between carcinosarcoma and sarcomatoid carcinoma. [10] Conversely, another study of 301 cases concluded that the survival rate of sarcomatoid carcinoma is better than that of carcinosarcoma. [11] As noted in a recent review, the latter study has a limitation of not performing a central pathology review. [15] However, stratifying by T stage in survival analysis, which was not conducted in the former study, provides superiority of the latter study. Indeed, in the former study, there were more pT4 cases in the sarcomatoid carcinoma group than in the carcinosarcoma group, leaving the possibility that failure to show a significant difference in survival was due to selection bias. Given that carcinosarcoma and sarcomatoid carcinoma of the urinary tract may differ in clinical outcome, we believe that the distinction should be made between these 2 entities for further investigation.
In summary, carcinosarcoma of the upper urinary tract accompanied by ureteral duplication is extremely rare. Further studies are warranted to elucidate the association between Table 1 Immunohistochemical findings of the carcinosarcoma in the ureteropelvic junction.
Antibodies to

Carcinomatous component
Sarcomatous component Budd (1987) [25] 40 M urothelial (transitional cell) carcinoma right upper moiety pelvis complete painless hematuria nephrectomy not described not described not described not described not described 4 Sreenevasan et al. (1987) [26] (1989) [27] 47 M urothelial (transitional cell) carcinoma with osseous metaplasia left ureter not described flank discomfort, abdominal distension, dysuria nephroureterectomy not described not described not described not described not described 6
Gepi-Atte et al.
(1991) [28] 74 M urothelial (transitional cell) carcinoma left upper moiety ureter (distal) incomplete painless hematuria nephroureterectomy pT2 not described not described not described not described 7 Asase et al.
(1992) [29] (1996) [31] 42 F leiomyosarcoma left upper moiety pelvis incomplete none nephrectomy pT2a not described not described not described not described 10 Tan et al. (1996) [32] [38] 68 F urothelial (transitional cell) carcinoma right upper moieter ureter (proximal) complete flank pain nephroureterectomy not described (À) not described not described not described 19 Boris et al. (2006) [39] 51 F urothelial (transitional cell) carcinoma right upper and lower moiety ureter (distal) incomplete hematuria nephroureterectomy pT1 or less * not described not described not described not described 20 Chen et al. (2011) [40] 
